In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine
复制标题
DOI：
10.1148/radiol.2017162610
复制
发表时间：
2018-05-01
期刊：
影响因子：
19.7
通讯作者：
Lewis, Jason S.
中科院分区：
文献类型：
--
作者：
Dunphy, Mark P. S.;Harding, James J.;Lewis, Jason S.
目的：评价谷氨酰胺类似物放射性显像剂氟18-(2S，4R)-4-氟谷氨酰胺(FGln)的临床安全性、药代动力学和肿瘤影像学特征。材料和方法：本研究由机构审查委员会批准，并根据《赫尔辛基宣言》和《健康保险携带和责任法案》在美国食品和药物管理局批准的研究新药申请下进行。所有患者均提供书面知情同意书。在2013年1月至2016年10月期间，25名成年癌症患者接受了静脉推注FGln示踪剂(平均为244MBq+/-118，
Purpose: To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent.Materials and Methods: This study was approved by the institutional review board and conducted under a U.S. Food and Drug Administration-approved Investigational New Drug application in accordance with the Helsinki Declaration and the Health Insurance Portability and Accountability Act. All patients provided written informed consent. Between January 2013 and October 2016, 25 adult patients with cancer received an intravenous bolus of FGln tracer (mean, 244 MBq +/- 118,